Closed-loop system enhances synaptic plasticity in patients' neurons, suggesting a new path for neurodegenerative therapy.
Background: Synaptic connectivity is compromised in neurodegenerative diseases; yet, current stem cell interventions are unable to control graft–host integration. Methods: We propose a closed-loop approach connecting optogenetics, three-dimensional (3D)-bioprinted neural grafts and activity-dependent plasticity for the dynamic restoration of injured circuits. The device utilises patients’ neurons, derived from induced pluripotent stem cells, that express channelrhodopsin-2. These neurons can be optimised to perform optical stimulation in patterns that replicate natural firing patterns, thereby facilitating functional synaptic re-writing. The addition of astrocyte co-cultures is necessary to produce synaptogenic factors, which can stabilize nascent connections. A fibrin-hyaluronic acid hydrogel matrix is used for structural support during the 3D bioprinting process. The graft design includes microfluidic canals for optic probe arrays as well as for real-time readout in the form of calcium imaging and electrophysiology. In addition, magnetic resonance imaging-guided implantation targets degenerated pathways detected by diffusion tensor imaging (DTI) to guarantee that the implantations are anatomically precise. Theta-burst stimulation paradigms induce long-term potentiation in graft-to-host connections, mediated by spike-timing-dependent plasticity rules. This methodology is unique in that it combines optogenetic control with bio-printed tissue engineering, enabling spatiotemporal control of the synaptic repair process. Results: In experiments, we demonstrate the robust survival of grafts in vitro and their functional connectivity with adaptive closed-loop modulation stimulation parameters, as observed in the activity. Conclusions: The system overcomes key deficiencies of current therapies, including the passive integration of grafts and the lack of controlled synaptic formation, and represents a scalable approach towards personalised treatment for neurodegenerative diseases. Its modular architecture makes it compatible with clinical workflow and could accelerate translation.
No takes yet. Share an insight, caveat, or question.
Alamer et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: